Development of a new Attention Rating Scale
Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
This study is testing a new Attention Rating Scale to see how well it measures attention in healthy adults and those with conditions like depression, ADHD, and insomnia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Peking University Sixth Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06207279 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop and validate the Attention Rating Scale (ARS) to assess attention in healthy adults and those with conditions like Major Depressive Disorder (MDD), ADHD, and insomnia. The study involves administering the ARS to 60 healthy subjects to evaluate its reliability and validity, using established tests like the Attention Network Test (ANT) as benchmarks. Participants will undergo retesting to assess consistency, and various statistical analyses will be performed to ensure the scale's effectiveness in measuring attention-related factors.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 60 diagnosed with MDD, ADHD, or chronic insomnia who meet specific inclusion criteria.
Not a fit: Patients with other DSM-5 mental disorders or those currently undergoing treatments that affect attention may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable tool for assessing attention disturbances in various patient populations, leading to better-targeted interventions.
How similar studies have performed: While the approach of developing a new attention assessment tool is common, the specific focus on the ARS and its validation in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Major Depressive Disorder (MDD) or attention deficit hyperactivity disorder (ADHD) diagnosed according to DSM-5, or Chronic Insomnia Disorder diagnosed according to ICSD-3 2. Ages between 18 and 60 years old 3. Right-handed 4. Educational level ≥5 years or IQ ≥90, capable of understanding and reading Chinese. Exclusion Criteria: 1. Currently diagnosed with any other DSM-5 mental disorders (according to MINI 7.0) or ICSD-3 sleep-wake disorders, apart from MDD, ADHD or insomnia disorder 2. Currently and past history of neurological disorders and physical illnesses with subjectives 3. Consumed alcohol in the week preceding the enrollment 4. Using antidepressants, antipsychotics, mood stabilizers, or other central nervous system-acting drugs for at least 4 weeks in the current episode 5. Undergoing any physical treatments such as ECT, neuromodulation therapy or Traditional Chinese Medicine treatment in the past 6 months 6. Refused to sign the informed consent form
Where this trial is running
Beijing, Beijing
- Peking University Sixth Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Xueqin Wang, doctor — Peking University Sixth Hospital
- Study coordinator: Xinyang Zhang, master
- Email: zhangxinyang2022@bjmu.edu.cn
- Phone: +8610-62723770
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.